Table 1.

Effects of SGLT2 inhibitors on body weight in obese individuals without type 2 diabetes

Reference, year	Duration (week)	N	Treatment arms	Bodyweight change from baseline (kg)	Other effects
SGLT2 inhibitors
Bays et al. 2014 [29]	12	376	Placebo Canagliflozin 50 mg Canagliflozin 100 mg Canagliflozin 300 mg	− 1.1 − 1.9 − 2.8 − 2.4	↓ BMI, SBP ↑ UGE/creatinine ratio, LDL-C/HDL-C, IWQOL-Lite total scores = TG, HDL-C, FPG, HbA1c, pulse rate
Napolitano et al. 2014 [82]	8	30	Placebo + diet (− 500 cal) Remogliflozin etaborate 250 mg + diet (− 500 cal) Sergliflozin etaborate 1,000 mg + diet (− 500 cal)	− 5.1 − 7.6 − 6.1	↓ Fat mass, fat free mass, leptin/adiponectin ↑ UGE
Ramirez-Rodriguez et al. 2018 [23]	12	24	Placebo Dapagliflozin 10 mg	− 1.0 − 3.0	↓ FPG, uric acid
SGLT2 inhibitors +GLP1-RA
Lundkvist et al. 2016 [83]	24	50	Placebo Dapagliflozin 10 mg + Exenatide 2 mg	− 0.4 − 4.5	↓ VAT, SAT, TAT, HbA1c, 2-h PG, IFG, SBP ↑ UGE = total lean tissue, liver fat, serum lipids
Lundkvist et al. 2017 [21]	52	50	Dapagliflozin 10 mg + Exenatide 2 mg	− 5.7
SGLT2 inhibitors + phentermine
Hollander et al. 2017 [42]	26	335	Placebo Canagliflozin 300 mg Phentermine 15 mg Canagliflozin + Phentermine 15 mg	− 0.6 − 1.9 − 4.1 − 7.3	↓ SBP ↑ Pulse rate (Phentermine, Canagliflozin + Phentermine) = plasma lipids

BMI body mass index, SBP systolic blood pressure, UGE urinary glucose excretion, LDL-C low density lipoprotein-cholesterol, HDL-C high-density lipoprotein-cholesterol, IWQOL Impact of Weight on Quality of Life, TG triglycerides, FPG fasting plasma glucose, VAT visceral adipose tissue, SAT subcutaneous adipose tissue, TAT total adipose tissue, 2-h PG 2-h post-OGTT plasma glucose, IFG impaired fasting glucose, ↓ reduction, ↑ increase, = no change